CRT Capital initiated coverage on Ultragenyx Pharma (NASDAQ: RARE) with a Buy rating and a price target of $90.00.

For an analyst ratings summary and ratings history on Ultragenyx Pharma click here. For more ratings news on Ultragenyx Pharma click here.

Shares of Ultragenyx Pharma closed at $59.96 yesterday.